Follow the FIVE PRIME THERAPEUTICS INC stock price and the full insider trade history of the company, a listed equity based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Market capitalisation: €10.7bn. The latest transaction was reported on 8 February 2016 (Levée d'options). Among the most active insiders: Sarena Francis Willard. The full history is openly available.
25
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
13 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate FIVE PRIME THERAPEUTICS INC Buy (bullish), based on 22 analysts. Average price target: US$264.45.
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 14,479 of 28,017 companies
51.1
score / 100
Value
43
Quality
59
FCF yld3.4%
Earn yld3.0%
EV/EBITDA21.6x
ROE21%
Gross mgn36%
Net mgn7.5%
Debt/EBITDA3.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
FIVE PRIME THERAPEUTICS INC is a biopharmaceutical company focused on developing innovative therapies for the treatment of cancer and other serious diseases. It is listed on NASDAQ under the ticker FPRX.